TY - JOUR
T1 - Nanocarriers: more than tour de force for thymoquinone
AU - Rathore, Charul
AU - Rathbone, Michael J
AU - Chellappan, Dinesh K
AU - Tambuwala, Murtaza M
AU - Pinto, Terezinha De Jesus A
AU - Dureja, Harish
AU - Hemrajani, Chetna
AU - Gupta, Gaurav
AU - Dua, Kamal
AU - Negi, Poonam
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Introduction: Thymoquinone (TQ), 2-isopropyl-5-methylbenzo-1, 4-quinone, the main active constituent of Nigella sativa (NS) plant, has been proven to be of great therapeutic aid in various in vitro and in vivo conditions. Despite the promising therapeutic activities of TQ, this molecule is not yet in the clinical trials, restricted by its poor biopharmaceutical properties including photo-instability. Area covered: This review compiles the different types of polymeric and lipidic nanocarriers (NCs), encapsulating TQ for their improved oral bioavailability, and augmented in vitro and in vivo efficacy, evidenced on various pathologies. Furthermore, we provide a comprehensive overview of TQ in relation to its encapsulation approaches advancing the delivery and improving the efficacy of TQ. Expert opinion: TQ was first identified in the essential oil of Nigella sativa L. black seed. TQ has not been used in formulations because it is a highly hydrophobic drug having poor aqueous solubility. To deal with the poor physicochemical problems associated with TQ, various NCs encapsulating TQ have been tried in the past. Nevertheless, these NCs could be impending in bringing forth this potential molecule to clinical reality. This will also be beneficial for a large research community including pharmaceutical & biological sciences and translational researchers.
AB - Introduction: Thymoquinone (TQ), 2-isopropyl-5-methylbenzo-1, 4-quinone, the main active constituent of Nigella sativa (NS) plant, has been proven to be of great therapeutic aid in various in vitro and in vivo conditions. Despite the promising therapeutic activities of TQ, this molecule is not yet in the clinical trials, restricted by its poor biopharmaceutical properties including photo-instability. Area covered: This review compiles the different types of polymeric and lipidic nanocarriers (NCs), encapsulating TQ for their improved oral bioavailability, and augmented in vitro and in vivo efficacy, evidenced on various pathologies. Furthermore, we provide a comprehensive overview of TQ in relation to its encapsulation approaches advancing the delivery and improving the efficacy of TQ. Expert opinion: TQ was first identified in the essential oil of Nigella sativa L. black seed. TQ has not been used in formulations because it is a highly hydrophobic drug having poor aqueous solubility. To deal with the poor physicochemical problems associated with TQ, various NCs encapsulating TQ have been tried in the past. Nevertheless, these NCs could be impending in bringing forth this potential molecule to clinical reality. This will also be beneficial for a large research community including pharmaceutical & biological sciences and translational researchers.
KW - Nigella sativa
KW - Thymoquinone
KW - Nano formulations
KW - Bioavailability
KW - Polymeric nanoparticles
KW - Lipid-based formulations
UR - http://www.scopus.com/inward/record.url?scp=85079765707&partnerID=8YFLogxK
UR - https://www.tandfonline.com/doi/full/10.1080/17425247.2020.1730808
UR - https://pubmed.ncbi.nlm.nih.gov/32077770/?from_term=murtaza+tambuwala&from_sort=pubdate&from_pos=3
U2 - 10.1080/17425247.2020.1730808
DO - 10.1080/17425247.2020.1730808
M3 - Article
C2 - 32077770
SN - 1742-5247
VL - 17
SP - 479
EP - 494
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 4
ER -
